희귀유전질환심포지엄조직위원회
Rare Genetic Disease Symposium Organizing Committee
PROFILE
박영민 단장
대한민국 경제의 새로운 엔진: K-바이오 신약개발의 미래
글로벌 제약·바이오 산업은 AI 전환, 모달리티 다변화, 공급망 재편 등으로 빠르게 변화하고 있다. 한국은 최근 기술이전 성과를 확대하며 글로벌 신약개발 역량을 입증하고 있으나, 후기 임상 투자와 글로벌 개발·상업화 경험에는 여전히 한계가 존재한다. 본 발표에서는 K-신약개발의 성과와 과제를 살펴보고, 기술이전을 넘어 글로벌 블록버스터를 창출하기 위한 전주기 지원, 정책금융 및 글로벌 공동개발 전략의 필요성을 제시한다.
국가신약개발사업단
EDUCATION
1998-2000, Research Associate Scientist, School of Medicine, Yale University
1988-1991, Ph.D. in Medicine, Graduate School of Jeonbuk National University, Korea
1986-1988, M.Sc. in Medicine, Graduate School of Jeonbuk National University, Korea
1980-1986, M.D., College of Medicine, Jeonbuk National University, Korea
PROFESSIONAL EXPERIENCE
2026-Present, Board Member, Korea Support Committee for IVI (KSC)
2026-Present, Chair, 2026 Prix Galien Korea Awards Committee
2026-Present, Board Member, Korea National Enterprise for Clinical Trials (KoNECT)
2026-Present, Member, Deliberation Committee, Hongneung Innopolis
2024-Present, CEO, Korea Drug Development Fund
2023-2026, Professor, Department of Integrative Biological Sciences and Industry, Sejong University
2016-2022, Director, Medical Science Research Center(MRC), Ministry of Science and ICT, Korea
2016-2021, Director, Institute of Biomedical Sciences & Technology, Konkuk University, Korea
2013-2015, Director, Medical and Pharmaceutical Division, Basic Research Headquarters, National Research Foundation of Korea
RESEARCH ACTIVITIES & OTHERS
-
Chan Mi Lee, Yun Kyeong Kwon, Ji Eun Won, Jae Hee Lee, Dae Gwin Jeong, Jinhong Wie, Wan-Uk Kim, Hee Dong Han & Yeong-Min Park.Cancer nanovaccine plus doxorubicin and immune checkpoint blockade overcomes chemoresistance and delays postsurgical recurrence.J Nanobiotechnol(2026). https://doi.org/10.1186/s12951-026-04892-3
-
Lee SE, Lee CM, Won JE, Jang GY, Lee JH, Park SH, Kang TH, Han HD, Park YM. Enhancement of anticancer immunity by immunomodulation of apoptotic tumor cells using annexin A5 protein-labeled nanocarrier system. Biomaterials. 2022 Sep;288:121677. doi: 10.1016/j.biomaterials.2022.121677. Epub 2022 Jul 21. '교신저자' (IF 14)
-
Won JE, Byeon Y, Wi TI, Lee CM, Lee JH, Kang TH, Lee JW, Lee Y, Park YM, Han HD. Immune checkpoint silencing using RNAi-incorporated nanoparticles enhances antitumor immunity and therapeutic efficacy compared with antibody-based approaches.J Immunother Cancer. 2022 Feb;10(2): doi:10.1136/jitc-2021-003928 '교신저자' (IF 10.9)
-
Hyeon soo Kim, Sujin Kim, Soo Jung Shin, Yong Ho Park, Yunkwon Nam, Chae won Kim, Kang won Lee, Sung‑Min Kim, In Duk Jung, Hyun Duk Yang, Yeong‑Min Park, and Minho Moon. Gram-negative bacteria and their lipopolysaccharides in Alzheimer’s disease: Pathologic roles and therapeutic implications. TRANSLATIONAL NEURODEGENERATION. 2021. Dec. '교신저자' (IF 12.6)
-
Jang GY, Lee JW, Kim YS, Lee SE, Han HD, Hong KJ, Kang TH, Park YM. Interactions between tumor-derived proteins and Toll-like receptors. Exp Mol Med. 2020 Dec;52(12):1926-1935. '교신저자' (IF 12.8)
-
Tae Heung Kang, Jung Hwa Park, Andrew Yang, Hyun Jin Park, Sung Eun Lee, Young Seob Kim, Gun-Young Jang, Emily Farmer, Brandon Lam, Yeong-Min Park, Chien-Fu Hung. Annexin A5 as an immune checkpoint inhibitor and tumor-homing molecule for cancer treatment. Nat Commun 2020 Feb 28;11(1):1137. '교신저자‘ (IF 16.6)